AC-42
AC-42 is a selective M1 muscarinic receptor allosteric agonist. It is used in scientific research and has been shown to improve cognitive performance in animal studies, suggesting potential applications in the treatment of cognitive disorders such as Alzheimer's disease and schizophrenia.
Mechanism of Action[edit | edit source]
AC-42 works by selectively binding to the M1 muscarinic receptor, one of the five types of muscarinic acetylcholine receptors. These receptors are part of the G protein-coupled receptor family and are found in various parts of the body, including the brain, heart, and smooth muscles. By acting as an allosteric agonist, AC-42 enhances the receptor's response to its natural ligand, acetylcholine.
Potential Therapeutic Applications[edit | edit source]
The M1 muscarinic receptor is thought to play a crucial role in cognitive function, and its dysfunction has been implicated in various cognitive disorders. Preclinical studies have shown that AC-42 can improve cognitive performance in animal models, suggesting potential therapeutic applications in the treatment of cognitive disorders.
Alzheimer's Disease[edit | edit source]
Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Current treatments are largely symptomatic and do not halt disease progression. Given the role of the M1 muscarinic receptor in cognitive function, AC-42 has been investigated as a potential treatment for Alzheimer's disease.
Schizophrenia[edit | edit source]
Schizophrenia is a chronic mental disorder characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions. Cognitive impairment is a core feature of schizophrenia, and current treatments do not adequately address this aspect of the disorder. Preclinical studies have suggested that AC-42 may have potential as a cognitive enhancer in the treatment of schizophrenia.
Safety and Tolerability[edit | edit source]
As with any drug, the safety and tolerability of AC-42 are important considerations. While preclinical studies have shown promising results, further research is needed to fully understand the safety profile of AC-42.
See Also[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD